Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil

Genetics and Molecular Research

Volumn 4, Issue 1, 2005, Pages 18-30

  Pinto, Giovanny Rebouças ^a,b   Overal, David James ^b   De Moraes, Leopoldo Silva ^b   Van Den Berg, Ana Virgínia ^b   Lemos, José Alexandre Rodrigues ^c   Smith, Marília De Arruda Cardoso ^d   Burbano, Rommel Rodríguez ^b,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c Fund Ctro Hemoterapia Hematol P   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Classification; Cytogenetics; del(3)(p25); Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ARTICLE; BLAST CELL; BRAZIL; CHROMOSOME 3P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME MAP; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; FEMALE; HUMAN; KARYOTYPE; MALE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SYMPTOM; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KARYOTYPING; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 18044397297     PISSN: 16765680     EISSN: 16765680     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Arber, D.A. (2001). Realistic pathologic classification of acute myeloid leukemias. Am. J. Clin. Pathol. 115: 552-560.
2. Aul, C., Gattermann, N. and Schneider, W. (1995). Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk. Lymphoma 16: 247-262.
3. Bain, B.J. (1996). The bone marrow aspirate of healthy subjects. Br. J. Haematol. 94: 206-209.
4. Bain, B.J. (1999). The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk. Lymphoma 34: 443-449.
5. Balduini, C.L., Guarnone, R., Pecci, A., Centenara, E. and Ascari, E. (1997). International prognostic scoring system and other prognostic systems for myelodysplastic syndromes. Blood 90: 4232-4234.
6. Bellamy, W.T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T.M. and List, A.F. (2001). Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427-1434.
7. Bennett, J.M. (2000). World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int. J. Hematol. 72: 131-133.
8. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. and Sultan, C. (1982). Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51: 189-199.
9. Bennett, J.M., Brunning, R.D. and Vardiman, J.W. (2002). Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood 99: 3074-3075.
10. Cilloni, D., Gottardi, E., Messa, F., Fava, M., Scaravaglio, P., Bertini, M., Girotto, M., Marinone, C., Ferrero, D., Gallamini, A., Levis, A. and Saglio, G. (2003). Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol. 21: 1988-1995.
11. Culligan, D.J. and Jacobs, A. (1992). Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk. Res. 16: 4-5.
12. Dunbar, C. and Saunthararajah, Y. (2000). Myelodysplastic syndromes. In: Bone Marrow Failure Syndromes (Young, N.S., ed.). W.B. Saunders Co., Philadelphia, PA, USA, pp. 69-98.
13. Dunkley, S.M., Manoharan, A. and Kwan, Y.L. (2002). Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts. Blood 99: 3870-3871 (author reply 3871).
14. Fenaux, P., Morel, P. and Lai, J.L. (1996). Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 33: 127-138.
15. Gardais, J. (2000). Dyshaemopoiesis in adults: a practical classification for diagnosis and management. Leuk. Res. 24: 641-651.
16. George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel, J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H. and Warrier, I. (1996). Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88: 3-40.
17. Germing, U., Gattermann, N., Strupp, C., Aivado, M. and Aul, C. (2000). Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24: 983-992.
18. Giagounidis, A.A., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M. and Aul, C. (2004). Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18: 113-119.
19. Goyal, R., Qawi, H., Ali, I., Dar, S., Mundle, S., Shetty, V., Mativi, Y., Allampallam, K., Lisak, L., Loew, J., Venugopal, P., Gezer, S., Robin, E., Rifkin, S. and Raza, A. (1999). Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk. Res. 23: 357-364.
20. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. and Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
21. Greenberg, P., Bishop, M.R., Deeg, H.J., Estey, E., Erba, H., Gore, S., Nimer, S., O'Donnell, M., Tallman, M., Bennett, J., Estey, E. and Stone, R. (1998). NCCN practice guidelines for the myelodysplastic syndromes. Oncology 12: 53-80.
22. Greenberg, P., Anderson, J., de Witte, T., Estey, E., Fenaux, P., Gupta, P., Hamblin, T., Hellstrom-Lindberg, E., List, A., Mufti, G., Neuwirtova, R., Ohyashiki, K., Oscier, D., Sanz, G., Sanz, M. and Willman, C. (2000). Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J. Clin. Oncol. 18: 3447-3452.
23. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. and Bloomfield, C.D. (2000). The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod. Pathol. 13: 193-207.
24. Hofmann, W.K., Lubbert, M., Hoelzer, D. and Phillip Koeffler, H. (2004). Myelodysplastic syndromes. Hematol. J. 5: 1-8.
25. Howe, R.B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. and Hellstrom-Lindberg, E. (2003). The WHO classification of MDS does make a difference. Blood 103: 3265-3270.
26. Huret, J.L. (2002). FANCD2 (Fanconi anemia, complementation group D2).. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: 〈http://www.infobiogen.fr/services/chromcancer/Genes/FAD.html〉. Accessed March 8, 2004.
27. ISCN (1995). An International System for Human Cytogenetic Nomenclature (Mitelman, F., ed.). S. Karger, Basel, Switzerland.
28. Jaffe, E.S., Harris, N.L., Stein, H. and Vardiman, J.W. (2001). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. IARC, Lyon, France.
29. Johansson, B., Billstrom, R., Kristoffersson, U., Akerman, M., Garwicz, S., Ahlgren, T., Malm, C. and Mitelman, F. (1997). Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 11: 1207-1213.
30. Matsuda, A., Jinnai, I., Yagasaki, F., Kusumoto, S., Murohashi, I., Bessho, M., Hirashima, K., Honda, S., Minamihisamatsu, M., Fuchigami, K., Matsuo, T., Kuriyama, K. and Tomonaga, M. (1999). New system for assessing the prognosis of refractory anemia patients. Leukemia 13: 1727-1734.
31. Mecucci, C. and La Starza, R. (1999). Cytogenetics of myelodysplastic syndromes. Forum 9: 4-13.
32. Menke, D.M., Colon-Otero, G., Cockerill, K.J., Jenkins, R.B., Noel, P. and Pierre, R.V. (1992). Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am. J. Clin. Pathol. 98: 502-510.
33. Mhawech, P. and Saleem, A. (2001). Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit. Rev. Oncol. Hematol. 40: 229-238.
34. Nand, S. and Godwin, J.E. (1988). Hypoplastic myelodysplastic syndrome. Cancer 62: 958-964.
35. Neuwirtova, R., Mocikova, K., Musilova, J., Jelinek, J., Havlicek, F., Michalova, K. and Adamkov, M. (1996). Mixed myelodysplastic and myeloproliferative syndromes. Leuk. Res. 20: 717-726.
36. Nosslinger, T., Reisner, R., Koller, E., Gruner, H., Tuchler, H., Nowotny, H., Pittermann, E. and Pfeilstocker, M. (2001). Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98: 2935-2941.
37. Ohyashiki, J.H., Iwama, H., Yahata, N., Ando, K., Hayashi, S., Shay, J.W. and Ohyashiki, K. (1999). Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 5: 1155-1160.
38. Ost, A. and Reizenstein, P. (1992). Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk. Res. 16: 9-11.
39. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. and West, R. (1998). RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12: 887-892.
40. Paquette, R.L., Landaw, E.M., Pierre, R.V., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F. and Koeffler, H.P. (1993). N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82: 590-599.
41. Ramos, F., Fernandez-Ferrero, S., Suarez, D., Barbon, M., Rodriguez, J.A., Gil, S., Megido, M., Ciudad, J., Lopez, N., del Canizo, C. and Orfao, A. (1999). Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk. Res. 23: 283-290.
42. Richard, S. (2002). VHL. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: 〈http://www.infobiogen.fr/services/ chromcancer/Genes/VHLID132.html〉. Accessed March 8, 2004.
43. Rosati, S., Anastasi, J. and Vardiman, J. (1996). Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin. Hematol. 33: 111-126.
44. Scheres, J.M. (1972). Identification of two Robertsonian translocations with a Giemsa banding technique. Humangenetik 15: 253-256.
45. Shimazaki, K., Ohshima, K., Suzumiya, J., Kawasaki, C. and Kikuchi, M. (2000). Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br. J. Haematol. 110: 584-590.
46. Stary, A. and Sarasin, A. (2001). XPC. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 〈http://www.infobiogen.fr/services/ chromcancer/Genes/XPCID122.html〉. Consulted March 8, 2004.
47. Steensma, D.P. and Tefferi, A. (2003). The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk. Res. 27: 95-120.
48. Strupp, C., Gattermann, N., Giagounidis, A., Aul, C., Hildebrandt, B., Haas, R. and Germing, U. (2003). Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk. Res. 27: 397-404.
49. Tien, H.F., Tang, J.H., Tsay, W., Liu, M.C., Lee, F.Y., Wang, C.H., Chen, Y.C. and Shen, M.C. (2001). Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 112: 148-154.
50. Tricot, G.J. (1992). Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk. Res. 16: 5-6.
51. Vardiman, J.W., Harris, N.L. and Brunning, R.D. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
52. Verburgh, E., Achten, R., Maes, B., Hagemeijer, A., Boogaerts, M., De Wolf-Peeters, C. and Verhoef, G. (2003). Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J. Clin. Oncol. 21: 273-282.
53. Voso, M.T., Scardocci, A., Guidi, F., Zini, G., Di Mario, A., Pagano, L., Hohaus, S. and Leone, G. (2004). Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103: 698-700.